Colinz Laboratories Ltd

Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal.

Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector.

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggests a recalibration of price attractiveness amid a challenging market backdrop and evolving sector dynamics.

Colinz Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its recent market performance and peer comparisons, offers investors a fresh perspective on the stock’s price attractiveness amid a challenging industry backdrop.

Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company.

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70.

Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry.

Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance.

Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market.

Colinz Laboratories Ltd is experiencing substantial selling pressure, with its stock declining significantly over various time frames. The company has faced consecutive losses, underperforming against the Sensex and its sector. Factors contributing to this trend include trading below key moving averages and ongoing challenges in its market position.

Colinz Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹20.00 crores, reported its Q2 FY26 results that underscore deepening operational challenges. The company posted a net profit of ₹0.14 crores for the quarter ended September 2025, representing a modest 16.67% sequential increase from Q1 FY26 but a concerning 12.50% decline year-on-year. More troubling is the persistent revenue erosion, with net sales declining 25.27% YoY to ₹1.39 crores, marking the third consecutive quarter of double-digit YoY revenue contraction.